Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, v 3-integrin, and TGF- 1 in response to ANG II and high glucose

Belmadani S, Zerfaoui M, Boulares HA, Palen DI, Matrougui K. Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, v 3-integrin, and TGF1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol 295: H69–H76, 2008. First published May 2, 2008; doi:10.1152/ajpheart.00341.2008.—This study determines that vascular smooth muscle cell (VSMC) signaling through extracellular signal-regulated kinase (ERK) 1/2-mitogen-activated protein (MAP) kinase, v 3-integrin, and transforming growth factor (TGF)1 dictates collagen type I network induction in mesenteric resistance arteries (MRA) from Type 1 diabetic (streptozotocin) or hypertensive (HT; ANG II) mice. Isolated MRA were subjected to a pressurepassive-diameter relationship. To delineate cell types and mechanisms, cultured VSMC were prepared from MRA and stimulated with ANG II (100 nM) and high glucose (HG, 22 mM). Pressure-passivediameter relationship reduction was associated with increased collagen type I deposition in MRA from HT and diabetic mice compared with control. Treatment of HT and diabetic mice with neutralizing TGF1 antibody reduced MRA stiffness and collagen type I deposition. Cultured VSMC stimulated with HG or ANG II for 5 min increased ERK1/2-MAP kinase phosphorylation, whereas a 48-h stimulation induced latent TGF1, v 3-integrin, and collagen type 1 release in the conditioned media. TGF1 bioactivity and Smad2 phosphorylation were v 3-integrin-dependent, since 3-integrin antibody and v 3-integrin inhibitor (SB-223245, 10 M) significantly prevented TGF1 bioactivity and Smad2 phosphorylation. Pretreatment of VSMC with ERK1/2-MAP kinase inhibitor (U-0126, 1 M) reduced v 3-integrin, TGF1, and collagen type 1 content. Additionally, v 3-integrin antibody, SB-223245, TGF1-small-intefering RNA (siRNA), and Smad2-siRNA (40 nM) prevented collagen type I network formation in response to ANG II and HG. Together, these data provide evidence that resistance artery fibrosis in Type 1 diabetes and hypertension is a consequence of abnormal collagen type I release by VSMC and involves ERK1/2, v 3-integrin, and TGF1 signaling. This pathway could be a potential target for overcoming small artery complications in diabetes and hypertension.